Vor Biopharma (VOR) has jumped onto investors’ radar after strong Phase 3 data for telitacicept in IgA nephropathy, paired with upbeat new Wall Street coverage that frames the drug’s long term ...
Vor Biopharma (VOR) rose ~17% on Tuesday after J.P. Morgan initiated its coverage with an Overweight recommendation and a Dec. 2026 price target of $43, citing a potential blockbuster status for the ...
Vor Biopharma Inc. offers a high-risk, high-reward play on U.S. commercialization of telitacicept, a dual-target autoimmune drug approved in China. Complex warrant issuances and reverse stock split ...
The challenges facing biotechs amid the ongoing financial fallout have resulted in the winding down of one US biotech, Vor Bio, and job losses at a clutch of other firms. Cambridge, ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed.
Customer stories Events & webinars Ebooks & reports Business insights GitHub Skills ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback